Table 7 Results of scenario analyses
Scenario | Incremental costs | Incremental QALYs | ICER |
|---|---|---|---|
Exponential survival function for PFS | £17,366 | 0.62 | £27,789 |
Weibull survival function for PFS | £17,055 | 0.64 | £25,499 |
Log-normal survival function for PFS | £15,921 | 0.77 | £18,691 |
Gamma survival function for PFS | £17,193 | 0.61 | £27,318 |
Gompertz survival function for PFS | £17,578 | 0.59 | £30,099 |
Weibull survival function for PrePS and PPS | £16,288 | 0.72 | £20,368 |
Log-logistic survival function for PrePS and PPS | £16,240 | 0.57 | £22,284 |
Log-normal survival function for PrePS and PPS | £16,256 | 0.47 | £23,700 |
Gamma survival function for PrePS and PPS | £16,332 | 0.81 | £19,489 |
Gompertz survival function for PrePS and PPS | £16,127 | 0.75 | £19,905 |
Equal PrePS across arms | £16,015 | 0.68 | £20,639 |
OS by trial arm instead of PrePS and PPS | £15,536 | 0.73 | £21,357 |
Primary IRC assessment of PFS | £16,009 | 0.65 | £21,369 |
Investigator assessment of PFS | £16,586 | 0.91 | £18,737 |
Patients clinically ineligible for HSCT only | £16,257 | 0.79 | £20,195 |
All utilities based on Doorduijn 2005 [34] | £16,212 | 0.75 | £28,419 |
Using utility decrement for progressing based on Doorduijn 2005 [34] | £16,212 | 0.69 | £23,409 |